PD Dr. Marlen Haderlein

Medizinische Fakultät Department of Radiation Oncology

Pradictive Character of Immunophenotyping in peripheral Blood in Patients treated with PD-1 Immunocheckpoint Inhibitors with and without Radiotherapy (Prospective Phase IV Study ST-ICI) (2018) Hecht M, Donaubauer AJ, Harrer A, Rutzner S, Becker I, Lettmaier S, Haderlein M, et al. Conference contribution Repeating of local therapy of distant metastases increases overall survival in patients with synchronous metastasized rectal cancer-a monocentric analysis (2018) Haderlein M, Lettmaier S, Langheinrich M, Schmid A, Semrau S, Hecht M, Beck M, et al. Journal article Inflammatory cells infiltrating HPV positive and negative head and neck squamous cell carcinoma (2018) Distel L, Farhoumand D, Haderlein M, Fietkau R Conference contribution Inflammatory Cells in HPV positive and negative Head and Neck Tumors (2018) Distel L, Haderlein M, Farhoumand D, Fietkau R, Hecht M Conference contribution Dose Reduction in the Swallowing Area by De-intensification of Radiotherapy in Patients with Head and Neck Cancer in the postoperative Situation - first Plan Analyzes of the DIREKHT Study (2018) Haderlein M, Speer S, Hecht M, Merten R, Scherl C, Semrau S, Ott O, Fietkau R Conference contribution Metabolic Response of Short-term Induction Chemotherapy (IC) for Therapy Selection as well as Prediction of long-term local and systemic Therapy Success for Head and Neck cancer. The Results of 100 Patients (2017) Semrau S, Haderlein M, Schmidt D, Waldfahrer F, Scherl C, Lettmaier S, Kuwert T, et al. Conference contribution In head and neck cancer the number of dissected lymph nodes predicts mortality (2017) Haderlein M, Fietkau R Journal article Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis (2017) Haderlein M, Scherl C, Semrau S, Lettmaier S, Hecht M, Erber R, Iro H, et al. Journal article Combination of growth pattern and tumor regression identifies a high-risk group in neoadjuvant treated rectal cancer patients (2017) Jeßberger J, Erlenbach-Wuensch K, Posselt R, Haderlein M, Agaimy A, Fietkau R, Hartmann A, Distel L Journal article Response to 6 cycles of chemotherapy with FOLFIRINOX is predictive of overall survival in patients with locally advanced unresectable pancreatic cancer (2016) Haderlein M, Lubgan D, Lettmaier S, Semrau S, Wolf W, Golcher H, Hohenberger W, Fietkau R Conference contribution